Drug Trial Radar · NCT07427680
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
Last checked: Nov 20, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
99
Planned (sponsor's estimate)
Start
Mar 3, 2026
Primary completion
Mar 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Tangram Therapeutics PlcIndustry
- Sponsor type
- Industry
- First posted
- Feb 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-312-SC01 in healthy adults and multiple ascending doses in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Conditions
- Healthy Participants
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
TGM-312-SC01Drug
TGM-312-SC01 is an investigational medicinal product administered by subcutaneous injection according to a protocol-defined regimen.
PlaceboDrug
Placebo administered by subcutaneous injection according to a protocol-defined regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events [Safety and tolerability]Time frame: From start of study drug administration through 16 weeks after the last study drug administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Richmond Pharmacology
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.